Urothelial Cancer Therapeutics
1. Balversa patent expiration
Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations whose disease has progressed on or after prior pd-1 or pd-l1 inhibitor therapy; ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8895601 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478494 | JANSSEN BIOTECH | FGFR/PD-1 combination therapy for the treatment of cancer |
Aug, 2036
(10 years from now) | |
| US12037644 | JANSSEN BIOTECH | Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor |
Oct, 2035
(9 years from now) | |
| US10898482 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(10 years from now) | |
| US9464071 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2031
(5 years from now) | |
| US11077106 | JANSSEN BIOTECH | Cancer treatment |
Feb, 2038
(12 years from now) | |
| US11684620 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(10 years from now) | |
| US9902714 | JANSSEN BIOTECH | Quinoxaline derivatives useful as FGFR kinase modulators |
Mar, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2024 |
| New Indication(I-930) | Jan 19, 2027 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: 13 April, 2023
Market Authorisation Date: 12 April, 2019
Dosage: TABLET
How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage
BALVERSA family patents
